An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory

[Image: see text] The SARS-CoV-2 pandemic has necessitated the rapid development of prophylactic vaccines. Two mRNA vaccines have been approved for emergency use by the FDA and have demonstrated extraordinary effectiveness. The success of these mRNA vaccines establishes the speed of development and...

Descripción completa

Detalles Bibliográficos
Autores principales: Haabeth, Ole A. W., Lohmeyer, Julian J. K., Sallets, Adrienne, Blake, Timothy R., Sagiv-Barfi, Idit, Czerwinski, Debra K., McCarthy, Blaine, Powell, Abigail E., Wender, Paul A., Waymouth, Robert M., Levy, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265720/
https://www.ncbi.nlm.nih.gov/pubmed/34341771
http://dx.doi.org/10.1021/acscentsci.1c00361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265720/
https://www.ncbi.nlm.nih.gov/pubmed/34341771
http://dx.doi.org/10.1021/acscentsci.1c00361

Ejemplares similares